1: Oprah Winfrey Long-time talk show host Oprah Winfrey was recently featured in an exclusive interview with People magazine, during which she discussed her weight loss and her new book, "Enough: Your Health, Your Weight and What Its Like to Be Free." Winfrey, 71, began taking a GLP-1 medication in 2023 but attempted to quit just six months in to see if she could lose weight without it
SS-31 (Elamipretide): The First FDA-Approved Mitochondrial Therapeutic In September 2025, the FDA granted accelerated approval to Forzinity (elamipretide), marking a watershed moment in mitochondrial medicine
This finding in women is consistent with prior reports suggesting that GLP-1 RAs may produce more pronounced weight loss and glycemic improvements in female people, potentially due to sex-specific differences in GLP-1 receptor expression, pharmacodynamics, or hormonal interactions [21]
CJC-1295 has several modifications for improved pharmacokinetics, including the substitution of four amino acids in the original 29 amino acid chain, which improves the peptides stability and effectiveness [4, 5, 6]: At the second position, L-alanine is replaced with D-alanine, heightening resistance to the enzyme dipeptidyl peptidase-4 (DPP-4), which plays a crucial role in deactivating many peptide-based medications
Our guides on semaglutide with B12 and semaglutide methylcobalamin explain the rationale behind the combination and what benefits, if any, the added B12 provides
